Pfizer Inc. $PFE Shares Bought by Krilogy Financial LLC

Krilogy Financial LLC grew its stake in Pfizer Inc. (NYSE:PFE) by 22.9% during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 62,220 shares of the biopharmaceutical company’s stock after purchasing an additional 11,590 shares during the quarter. Krilogy Financial LLC’s holdings in Pfizer were worth $1,508,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Brighton Jones LLC raised its position in shares of Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after acquiring an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC raised its holdings in shares of Pfizer by 12.5% during the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock worth $498,000 after purchasing an additional 2,087 shares during the period. Tidal Investments LLC lifted its position in shares of Pfizer by 41.1% in the 4th quarter. Tidal Investments LLC now owns 268,933 shares of the biopharmaceutical company’s stock worth $7,135,000 after buying an additional 78,305 shares during the last quarter. Vident Advisory LLC acquired a new position in shares of Pfizer in the 4th quarter valued at about $248,000. Finally, iSAM Funds UK Ltd bought a new stake in shares of Pfizer during the 4th quarter valued at about $595,000. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Down 0.4%

PFE stock opened at $23.88 on Wednesday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The firm has a market capitalization of $135.77 billion, a P/E ratio of 12.70, a P/E/G ratio of 0.85 and a beta of 0.55. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $30.43. The company’s 50 day simple moving average is $24.73 and its 200-day simple moving average is $24.25.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.20. The firm had revenue of $14.65 billion for the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period in the previous year, the company posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 2nd. Investors of record on Friday, July 25th were paid a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 7.2%. The ex-dividend date of this dividend was Friday, July 25th. Pfizer’s dividend payout ratio is currently 91.49%.

Wall Street Analyst Weigh In

A number of brokerages have commented on PFE. Jefferies Financial Group lifted their target price on Pfizer from $32.00 to $33.00 and gave the company a “buy” rating in a research note on Wednesday, May 21st. Berenberg Bank reduced their price objective on Pfizer from $28.00 to $25.00 and set a “hold” rating for the company in a research report on Thursday, May 29th. Bank of America increased their target price on Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Morgan Stanley raised their target price on Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 6th. Finally, Citigroup upped their price target on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Pfizer presently has an average rating of “Hold” and a consensus target price of $28.12.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.